GR3004061T3 - - Google Patents

Info

Publication number
GR3004061T3
GR3004061T3 GR920400448T GR920400448T GR3004061T3 GR 3004061 T3 GR3004061 T3 GR 3004061T3 GR 920400448 T GR920400448 T GR 920400448T GR 920400448 T GR920400448 T GR 920400448T GR 3004061 T3 GR3004061 T3 GR 3004061T3
Authority
GR
Greece
Prior art keywords
bryostatin
linneaeus
bryozoan
phylum
denominated
Prior art date
Application number
GR920400448T
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GR3004061T3 publication Critical patent/GR3004061T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
GR920400448T 1986-07-28 1992-03-18 GR3004061T3 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/889,946 US4833257A (en) 1986-07-28 1986-07-28 Compositions of matter and methods of using same

Publications (1)

Publication Number Publication Date
GR3004061T3 true GR3004061T3 (el) 1993-03-31

Family

ID=25396026

Family Applications (1)

Application Number Title Priority Date Filing Date
GR920400448T GR3004061T3 (el) 1986-07-28 1992-03-18

Country Status (8)

Country Link
US (1) US4833257A (el)
EP (1) EP0264173B1 (el)
JP (1) JP2626889B2 (el)
AT (1) ATE71627T1 (el)
CA (1) CA1305476C (el)
DE (1) DE3776063D1 (el)
ES (1) ES2038664T3 (el)
GR (1) GR3004061T3 (el)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256646A (en) * 1990-07-27 1993-10-26 Bristol-Myers Squibb Company Antiviral antibiotic BU-4224V
US5072004A (en) * 1990-12-31 1991-12-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthetic conversion of bryostatin 2 into bryostatin 1
US5196447A (en) * 1991-08-08 1993-03-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting On Behalf Of Arizona State University Neristatin 1
US5436400A (en) * 1993-01-19 1995-07-25 Arizona Board Of Regents Isolation and structure of spongistatin 1
US5393897A (en) * 1993-07-02 1995-02-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structure of spongistatins 5,7,8 and 9
US5684036A (en) * 1994-02-18 1997-11-04 Harbor Branch Oceanographic Institution, Inc. Cytotoxic macrolides and methods of use
US5478861A (en) * 1994-02-18 1995-12-26 Harbor Branch Oceanographic Institution, Inc. Cytotoxic macrolides and methods of use
WO1997034598A1 (en) * 1996-03-20 1997-09-25 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of treating cancer using c-26 modified bryostatin
US7256286B2 (en) * 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
WO2001040214A1 (en) 1999-11-30 2001-06-07 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
EP1383540B1 (en) * 2000-07-31 2009-04-29 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7842727B2 (en) * 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
JP4824268B2 (ja) * 2001-05-02 2011-11-30 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 学習および記憶を増強させるためのカルボニックアンヒドラーゼ活性化剤
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US6900339B2 (en) 2002-04-30 2005-05-31 The University Of North Carolina At Chapel Hill Bryostatin composition and bryostatin acquisition methodologies
AU2003243272A1 (en) * 2002-05-22 2003-12-12 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
CN1678304B (zh) * 2002-07-02 2012-06-27 布朗歇特洛克菲勒神经科学研究所 苔藓抑制素类化合物在制备用于活化PKC而增强sAPPα分泌和改善认知的药物中的应用
CA2506504A1 (en) * 2002-11-20 2004-06-03 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
JP4668902B2 (ja) * 2003-08-07 2011-04-13 ヒーラー リミテッド 創傷治癒を促進するための薬剤組成物及び方法
TW201206425A (en) * 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
CA2587013A1 (en) * 2004-11-08 2006-05-18 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
CA2617003A1 (en) 2005-07-29 2007-02-08 Blanchette Rockefeller Neurosciences Institute Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory
NZ566083A (en) * 2005-08-29 2012-11-30 Healor Ltd Methods and compositions for prevention and treatment of diabetic and aged skin
CN103961347A (zh) 2006-07-28 2014-08-06 布朗歇特洛克菲勒神经科学研究所 刺激细胞生长、突触重塑和巩固长期记忆的方法
EP2959914A1 (en) * 2007-02-09 2015-12-30 Blanchette Rockefeller Neurosciences, Institute Therapeutic effects of bryologs on head trauma-induced memory impairment and brain injury
JP5872138B2 (ja) 2007-02-09 2016-03-01 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 虚血／卒中誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果
US20100310542A1 (en) * 2007-07-30 2010-12-09 Healor Ltd. Pharmaceutical Compositions for treating wouds and related methods
KR101397912B1 (ko) * 2009-02-24 2014-05-29 힐로 리미티드 여드름 및 기타 질환 치료용 비스파틴 치료제
WO2011083481A2 (en) 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of inflammatory disease and disorder
WO2012006510A1 (en) 2010-07-08 2012-01-12 Alkon Daniel L Fatty acid protein kinase c activators and anticoagulant for the treatment of stroke
CA2808660A1 (en) 2010-08-19 2012-02-23 Blanchette Rockefeller Neurosciences Institute Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators
EP3967299A1 (en) 2011-11-13 2022-03-16 Cognitive Research Enterprises, Inc. Pkc activators and combinations thereof
JP6440628B2 (ja) * 2012-11-27 2018-12-19 アフィオス コーポレーション 蘚苔地衣類組成物、その作製方法及び使用
US20180030095A1 (en) 2015-02-13 2018-02-01 George Robert Pettit Silstatin compounds
WO2016183252A1 (en) 2015-05-11 2016-11-17 Alkon, Daniel, L. Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele
WO2019094709A1 (en) 2017-11-09 2019-05-16 Pettit George R Betulastatin compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
JPS60174418A (ja) * 1984-02-18 1985-09-07 Ishikawajima Harima Heavy Ind Co Ltd 下水あるいはし尿汚泥等の流動層式焼却装置
US4611066A (en) * 1984-08-10 1986-09-09 Arizona State University Bryostatins 4 to 8

Also Published As

Publication number Publication date
US4833257A (en) 1989-05-23
JPS63183585A (ja) 1988-07-28
JP2626889B2 (ja) 1997-07-02
DE3776063D1 (en) 1992-02-27
EP0264173A3 (en) 1988-07-13
ES2038664T3 (es) 1993-08-01
CA1305476C (en) 1992-07-21
EP0264173A2 (en) 1988-04-20
ATE71627T1 (de) 1992-02-15
EP0264173B1 (en) 1992-01-15

Similar Documents

Publication Publication Date Title
DE3776063D1 (en) Bryostatine.
AU3264489A (en) 2-substituted-4-substituted-1,3-dioxalanes, synthesis and use thereof
EP0245518A4 (en) ISOFLAVONE DERIVATIVES, THEIR SALTS AND ONCOSTATIC AGENTS AND IMMUNOSUPPRESSANTS.
FI930977A0 (fi) Taxanderivat, deras framstaellning och onkologiska anvaendning
AU6307586A (en) Quinoline derivatives
ES544752A0 (es) Un procedimiento para la preparacion de carbapenems.
AU7147387A (en) Six-membered N-heterocyclic derivatives of N'-substituted-N, N'-diacylhydrazines
AU7147287A (en) Five-membered N-heterocyclic derivatives of N'-substituted-N,N'-diacylhydrazines
AU600054B2 (en) 2,5,6,7-tetranor-18,18,19,19-tetradehydro-4,8-inter-m- phenylene pgi2 derivatives
CA1265131C (en) ERYTHROMYCYLAMINE DERIVATIVES
WO1988003922A3 (en) Thiophenesulfonamide herbicides
IL107242A0 (en) Derivatives of benzeneborinic acid, preparation thereof and use thereof as synthetic intermediates
FR2597105B1 (fr) Derives antibiotiques de la famille des 20-0-acyl-19,20-enolmacrolides
ES2014041A6 (es) Un procedimiento para preparar un derivado de amina.
PH24927A (en) Derivatives of substituted 1,2,3-thiadiazole-4-thiolate compounds
AR241135A2 (es) "derivados de n-triazinil-n-sulfamoilurea herbicidamente activos y formulacion herbicida que los contiene".
FI862861A (fi) Regelbar baeranordning.
LV5622A3 (lv) Panemiens aizvietotu 1,3,4,9-tetrahidropirano(3,4-b)indol-1-il-etikskabju vai to farmaceitiski saderigu salu iegusanai